Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
复制标题
DOI：
10.2174/1874471011104040283
复制
发表时间：
2011-10
影响因子：
2.3
通讯作者：
Zalutsky MR
中科院分区：
文献类型：
--
作者：
Vaidyanathan G;Zalutsky MR
使用带有α发射放射性核素标记的药剂的靶向放射治疗正在获得牵引力，已经进行或正在进行的几项临床试验以及其他处于高级规划阶段的临床试验。最常用的α放射性核素是213 Bi，211 At，223 Ra和225 Ac。虽然每一种都有优点和缺点，但可以说211 At可能是基于其半衰期，衰变方案和化学性质的最通用的。另一方面，对于靶向骨转移，223Ra是理想的放射性核素，因为简单的阳离子镭可用于此目的。本文就211At标记放射性药物的应用进展进行综述，并对223Ra在α粒子靶向放射治疗中的应用现状进行综述。
Targeted radiotherapy using agents tagged with α-emitting radionuclides is gaining traction with several clinical trials already undertaken or ongoing, and others in the advanced planning stage. The most commonly used α-emitting radionuclides are 213Bi, 211At, 223Ra and 225Ac. While each one of these has pros and cons, it can be argued that 211At probably is the most versatile based on its half life, decay scheme and chemistry. On the other hand, for targeting bone metastases, 223Ra is the ideal radionuclide because simple cationic radium can be used for this purpose. In this review, we will discuss the recent developments taken place in the application of 211At-labeled radiopharmaceuticals and give an overview of the current status of 223Ra for targeted α-particle radiotherapy.